President Trump targets Amazon in his call for U.S. Postal Service to charge higher delivery prices on the ecommerce giant.

Laura Hermes

2018-01-03 08:38:00 Wed ET

President Trump targets Amazon in his call for U.S. Postal Service to charge high delivery prices on the ecommerce giant. Trump picks another fight with an online retail giant that he has criticized during the presidential campaign. Now U.S.P.S. runs a substantial net loss and serves as an independent agency within the federal government with minimal tax dollars for operating expenses. Package delivery has become an increasingly important part of U.S.P.S. business because the Internet has led to a sharp decline in the amount of first-class letters.

U.S.P.S. delivers 60%+ of Amazon packages with about 4 million parcels per day during the current peak year-end holiday shipping season. Amazon's other major carriers are UPS and FedEx that collectively account for about 30% of Amazon parcels. Both UPS and FedEx have long voiced their key concerns and complaints about U.S.P.S. cost structure. In fact, U.S.P.S. deficit has ballooned to about $62 billion, and this situation cannot sustain in the long run. If the Trump administration induces U.S.P.S. to charge more on Amazon packages, the ecommerce giant may pass higher costs onto key American consumers and small businesses. Worldwide delivery operations may become too expensive to the detriment of consumers. The status quo remains a time-worn impasse between ecommerce and postal service. 

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Becky Berkman

2019-08-09 18:35:00 Friday ET

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups; whereas, the government should now reassert itself in terms o

+See More

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth.

Chanel Holden

2019-11-19 09:33:00 Tuesday ET

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth.

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth. Despite a sharp slowdown in U.S. services and utilities

+See More

Capital structure theory and practice

Jonah Whanau

2022-03-15 10:32:00 Tuesday ET

Capital structure theory and practice

Capital structure theory and practice  The genesis of modern capital structure theory traces back to the seminal work of Modigliani and Miller (1958

+See More

We assess the global fiscal deficits and sovereign debt burdens in America, Europe, and many other countries worldwide.

James Campbell

2027-01-31 12:25:00 Sunday ET

We assess the global fiscal deficits and sovereign debt burdens in America, Europe, and many other countries worldwide.

In recent decades, many governments have chosen to run high fiscal deficits on top of sovereign debt mountains so that greater government intervention still

+See More

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Laura Hermes

2019-09-09 20:38:00 Monday ET

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization.

Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More